Last updated on April 2018

Phase II Study of BNC210 in PTSD


Brief description of study

This is a randomized, double-blind, placebo-controlled study, evaluating the effects of BNC210 versus placebo on the symptoms of Post-Traumatic Stress Disorder, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5).

The secondary objectives of the study are to evaluate the effects of BNC210 on anxiety, depression, global functioning and patient reported outcomes in patients with PTSD. Safety and tolerability of BNC210 will also be assessed. Study participants will receive 12 weeks of blinded treatment followed by a 3 week follow-up period.

Clinical Study Identifier: NCT02933606

Contact Investigators or Research Sites near you

Start Over

BNC210 restore study

Oceanside, CA United States

BNC210 restore study

Rancho Mirage, CA United States

BNC210 restore study

Redlands, CA United States

BNC210 restore study

Riverside, CA United States

BNC210 restore study

Gainesville, FL United States

BNC210 restore study

Jacksonville, FL United States

BNC210 restore study

Lauderhill, FL United States

BNC210 restore study

North Miami, FL United States

BNC210 restore study

Oakland Park, FL United States

BNC210 restore study

Orlando, FL United States

BNC210 restore study

Hoffman Estates, IL United States

BNC210 restore study

Overland Park, KS United States

BNC210 restore study

New Bedford, MA United States

BNC210 restore study

Lincoln, NE United States

BNC210 restore study

Las Vegas, NV United States

BNC210 restore study

Berlin, NJ United States

BNC210 restore study

Canton, OH United States

BNC210 restore study

Memphis, TN United States

BNC210 restore study

Dallas, TX United States

BNC210 restore study

San Antonio, TX United States

BNC210 restore study

Penrith, Australia

BNC210 restore study

Auchenflower, Australia

BNC210 restore study

Toowong, Australia

BNC210 restore study

Elizabeth Vale, Australia

BNC210 restore study

St Kilda, Australia